| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
2,970,000 |
| Market
Cap: |
1.11(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.3751 - $0.3751 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile OncoSec Medical is a immuno-oncology company focused on designing, developing and commercializing intra-tumoral DNA-based therapeutics to stimulate and to guide anti-tumor immune responses for the treatment of cancers. Co.'s main technology platform ImmunoPulse® is a drug-device therapeutic modality platform comprised of proprietary intratumoral electroporation (EP) delivery devices (the OncoSec Medical System (OMS) EP Device) and a proprietary DNA plasmid. The OMS EP Device is designed to deliver plasmid DNA-encoded drugs into a solid tumor and promote an immunological response against cancer. Co.'s main product candidate is a DNA-encoded interleukin-12 called tavokinogene telseplasmid.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
0 |
607 |
| Total Sell Value |
$0 |
$0 |
$0 |
$362 |
| Total People Sold |
0 |
0 |
0 |
1 |
| Total Sell Transactions |
0 |
0 |
0 |
3 |
| End Date |
2024-02-22 |
2023-11-21 |
2023-05-23 |
2022-05-23 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Sirtex Medical Us Holdings, Inc. |
See Remarks |
– – • |
2020-08-19 |
4 |
B |
$3.25 |
$7,796,100 |
I/I |
2,398,800 |
2,399,800 |
1.5 |
- |
|
| O'connor Daniel |
CEO and President |
• • – |
2020-07-31 |
4 |
S |
$4.20 |
$13,159 |
D/D |
(3,133) |
105,962 |
|
- |
|
| Foerter Kellie Malloy |
Chief Operating OfficerOfficer |
• – – |
2020-07-27 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
31,494 |
|
- |
|
| O'connor Daniel |
CEO and President |
• • – |
2020-05-29 |
4 |
D |
$2.23 |
$99,170 |
D/D |
(44,471) |
109,095 |
|
- |
|
| O'connor Daniel |
CEO and President |
• • – |
2020-05-29 |
4 |
A |
$0.00 |
$0 |
D/D |
90,580 |
153,566 |
|
- |
|
| Delaversano Robert J |
Principal Accounting Officer |
• – – |
2020-05-29 |
4 |
D |
$2.23 |
$19,354 |
D/D |
(8,679) |
16,683 |
|
- |
|
| Delaversano Robert J |
Principal Accounting Officer |
• – – |
2020-05-29 |
4 |
A |
$0.00 |
$0 |
D/D |
25,362 |
25,362 |
|
- |
|
| O'connor Daniel |
CEO and President |
• • – |
2020-04-30 |
4 |
S |
$1.79 |
$5,504 |
D/D |
(3,075) |
62,986 |
|
- |
|
| Dhillon Avtar S |
Director |
– • – |
2020-04-17 |
4 |
A |
$1.55 |
$19,375 |
D/D |
12,500 |
62,052 |
|
- |
|
| O'connor Daniel |
CEO and President |
• • – |
2020-01-31 |
4 |
S |
$1.96 |
$5,202 |
D/D |
(2,654) |
66,061 |
|
- |
|
| O'connor Daniel |
CEO and President |
• • – |
2019-10-31 |
4 |
S |
$2.16 |
$4,596 |
D/D |
(2,128) |
68,715 |
|
- |
|
| Bonstein Sara |
CFO/COO |
• – – |
2019-10-16 |
4 |
S |
$2.01 |
$2,233 |
D/D |
(1,111) |
42,740 |
|
- |
|
| O'connor Daniel |
CEO and President |
• • – |
2019-07-31 |
4 |
D |
$2.23 |
$4,808 |
D/D |
(2,156) |
70,843 |
|
- |
|
| Alpha Holdings, Inc. |
Director |
– • • |
2019-07-17 |
4 |
B |
$2.57 |
$77,100 |
I/I |
30,000 |
1,611,000 |
2.25 |
- |
|
| Bonstein Sara |
CFO/COO |
• – – |
2019-07-16 |
4 |
D |
$2.42 |
$2,689 |
D/D |
(1,111) |
43,851 |
|
- |
|
| Alpha Holdings, Inc. |
Director |
– • • |
2019-07-16 |
4 |
B |
$2.34 |
$140,400 |
I/I |
60,000 |
1,581,000 |
2.25 |
- |
|
| Alpha Holdings, Inc. |
Director |
– • • |
2019-07-15 |
4 |
B |
$2.22 |
$66,600 |
I/I |
30,000 |
1,521,000 |
2.25 |
- |
|
| Alpha Holdings, Inc. |
Director |
– • • |
2019-05-22 |
4/A |
B |
$3.14 |
$1,541,740 |
D/D |
491,000 |
1,491,000 |
3.92 |
- |
|
| Alpha Holdings, Inc. |
Director |
– • • |
2019-05-22 |
4 |
B |
$3.14 |
$1,541,740 |
D/D |
491,000 |
10,491,000 |
3.92 |
- |
|
| O'connor Daniel |
CEO and President |
• • – |
2019-04-30 |
4 |
D |
$0.57 |
$12,067 |
D/D |
(21,357) |
729,992 |
|
- |
|
| Bonstein Sara |
CFO/COO |
• – – |
2019-04-16 |
4 |
D |
$0.60 |
$6,662 |
D/D |
(11,102) |
449,629 |
|
- |
|
| O'connor Daniel |
CEO and President |
• • – |
2019-01-31 |
4 |
D |
$0.88 |
$22,280 |
D/D |
(25,318) |
751,349 |
|
- |
|
| Bonstein Sara |
CFO/COO |
• – – |
2019-01-16 |
4 |
D |
$0.69 |
$9,165 |
D/D |
(13,379) |
460,731 |
|
- |
|
| O'connor Daniel |
CEO and President |
• • – |
2018-12-24 |
4 |
A |
$0.00 |
$0 |
D/D |
750,000 |
776,667 |
|
- |
|
| Demesa James M |
Director |
– • – |
2018-12-17 |
4 |
A |
$0.77 |
$1,155 |
D/D |
1,500 |
22,501 |
|
- |
|
121 Records found
|
|
Page 2 of 5 |
|
|
